Manish Sagar, MD
Infectious Disease · Boston, MANPI 1811954050
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,217 of the $1,829 with a category attached, or 66.5%. 5 manufacturers reported payments, led by Cepheid at 32.8% of the total. Reporting peaked in 2021 at $817 and has fallen 51.0% since, to $400 in 2024.
Across 5 payments — averaging $365.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cepheid$600
- Novocure GmbH$425
- Melinta Therapeutics, LLC$400
- BD$392
- Merck$13
Across 8 payments — averaging $49,268 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$394K
What the payments were for
- Consulting fees$1,21767%
- Speaking & faculty fees$60033%
- Education$131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cepheid | 1 | $600 |
| Novocure GmbH | 1 | $425 |
| Melinta Therapeutics, LLC | 1 | $400 |
| BD | 1 | $392 |
| Merck | 1 | $13 |
How this compares
$1,829 in reported general payments places this provider in the 75th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 117 | $463,375 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 48 | $212,938 |
| JulucaDolutegravir/Rilpivirine | 50 | $185,472 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 42 | $140,971 |
| TivicayDolutegravir Sodium | 12 | $28,644 |
| Rosuvastatin Calcium | 70 | $1,257 |
| Betamethasone Dipropionate | 13 | $401 |
| Atorvastatin Calcium | 47 | $368 |
| Amlodipine Besylate | 43 | $343 |
| Hydrochlorothiazide | 45 | $237 |
| Metformin Hcl ErMetformin Hcl | 12 | $211 |
| Omeprazole | 23 | $180 |
| Oxycodone Hcl | 13 | $161 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 13 | $135 |
| Pregabalin | 13 | $126 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.